论文部分内容阅读
长期接受血液透析(HD)患者几乎均有贫血,其主要原因可能为红细胞生成降低。本文报道去铁胺(DFO)对此类患者的红细胞生成作用。受试者为24例HD患者,男女各12例,年龄20-70岁,均有非小红细胞性贫血。受试者随机分为两组,治疗组16例,于每次透析结束时以DFO1g静注,每周3次,平均治疗74个月。对照组8例不给药。结果:治疗第6个月时,治疗组血色素(Hb)由治疗前7.2增至9.lg/dl(P<0.01),6个月的输血量由3.0降至1.8单位(P<0.05),但停止DFO后Hb又逐渐降至原来水平。对照组治疗前后无明显改变。治疗组网织红细胞及红细胞肌酸值均升高
Long-term hemodialysis (HD) patients have almost all anemia, the main reason may be reduced erythropoiesis. This article reports deferoxamine (DFO) on these patients erythropoietic role. Subjects were 24 HD patients, 12 males and 12 females, aged 20-70 years old, all with non-microcytic anemia. Subjects were randomly divided into two groups, treatment group of 16 patients, at the end of each dialysis with DFO1g intravenous injection three times a week, the average treatment of 74 months. The control group of 8 patients without medication. Results: At the 6th month of treatment, the hemoglobin (Hb) in the treatment group increased from 7.2 before treatment to 9.lg / dl (P <0.01), and the blood transfusion decreased from 3.0 to 1.8 at 6 months (P <0.05) But after stopping DFO Hb gradually dropped to the original level. The control group before and after treatment did not change significantly. Treatment group reticulocyte and erythrocyte creatine values were increased